» Articles » PMID: 24388409

Hepatolithiasis-associated Cholangiocarcinoma: Results from a Multi-institutional National Database on a Case Series of 23 Patients

Overview
Publisher Elsevier
Date 2014 Jan 7
PMID 24388409
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Few papers focused on association between hepatolithiasis (HL) and cholangiocarcinoma (CCC) in Western countries. The aims of this paper are to describe the clinical presentation, treatment, and postoperative outcomes of CCC with HL in a cohort of Western patients and to compare the surgical outcomes of these patients with patients with CCC without HL.

Materials And Methods: Among 161 patients with HL from five Italian tertiary hepato-biliary centers, 23 (14.3%) patients with concomitant CCC were analyzed. The results of surgery in these patients were compared with patients with CCC without HL.

Results: The 60.9% of patients with HL received the diagnosis of CCC intra- or postoperatively, with a resectability rate of 91.3%. The postoperative morbidity was 61.6%. The 1- and 3-year survival rates were 78.6% and 21.0%, respectively. The recurrence rate was 44.4% and the 3-year disease-free survival rates were 18.8%. The comparison with patients with CCC without HL showed a higher resectability rate (p = 0.02) and a higher frequency of earlier stage (p = 0.04) in CCC with HL. Biliary leakage was more frequent in CCC with HL group (p = 0.01) compared to CCC without HL group. We found no differences in overall and disease-free survival between the two groups.

Conclusions: Patients with HL and CCC showed a high resectability rate but a higher morbidity. Nevertheless, overall and disease-free survival of patients with CCC and HL showed no differences compared to those of patients with CCC without HL. Also in Western countries, HL needs a careful management for the possible presence of CCC.

Citing Articles

Evidence-based clinical practice guidelines for cholelithiasis 2021.

Fujita N, Yasuda I, Endo I, Isayama H, Iwashita T, Ueki T J Gastroenterol. 2023; 58(9):801-833.

PMID: 37452855 PMC: 10423145. DOI: 10.1007/s00535-023-02014-6.


Molecular Mechanisms Linking Risk Factors to Cholangiocarcinoma Development.

Ceci L, Zhou T, Lenci I, Meadows V, Kennedy L, Li P Cancers (Basel). 2022; 14(6).

PMID: 35326593 PMC: 8945938. DOI: 10.3390/cancers14061442.


Development and validation of a machine learning-based nomogram for prediction of intrahepatic cholangiocarcinoma in patients with intrahepatic lithiasis.

Shen X, Zhao H, Jin X, Chen J, Yu Z, Ramen K Hepatobiliary Surg Nutr. 2022; 10(6):749-765.

PMID: 35004943 PMC: 8683924. DOI: 10.21037/hbsn-20-332.


Development and Validation of a Radiomic-Based Model for Prediction of Intrahepatic Cholangiocarcinoma in Patients With Intrahepatic Lithiasis Complicated by Imagologically Diagnosed Mass.

Xue B, Wu S, Zheng M, Jiang H, Chen J, Jiang Z Front Oncol. 2021; 10:598253.

PMID: 33489897 PMC: 7817533. DOI: 10.3389/fonc.2020.598253.


Incidence and Prognosis of Subsequent Cholangiocarcinoma in Patients with Hepatic Resection for Bile Duct Stones.

Kim H, Kang T, Swan H, Kang M, Kim N, Ahn H Dig Dis Sci. 2018; 63(12):3465-3473.

PMID: 30171402 DOI: 10.1007/s10620-018-5262-6.